Hunter syndrome, also known as mucopolysaccharidosis II (MPS II), has long been considered one of the most complex and rare genetic disorders, primarily affecting young boys. But recent developments in biotechnology and pharmaceuticals are breathing new hope into families and healthcare providers across the globe. So what’s changing in the world of treatment — and could this signal...